A
Annovis Bio, Inc. (ANVS)
NYQ – Real Time Price. Currency in USD
1.72
+0.07 (4.24%)
At close: Jun 26, 2026, 4:00 PM EDT
1.74
+0.02 (1.42%)
After-hours: Jun 26, 2026, 7:39 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NYQ – Real Time Price. Currency in USD
1.72
+0.07 (4.24%)
At close: Jun 26, 2026, 4:00 PM EDT
1.74
+0.02 (1.42%)
After-hours: Jun 26, 2026, 7:39 PM EDT
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development |
| Dr. Maria L. Maccecchini Ph.D. | Founder, Acting CFO, CEO, President & Executive Director |
| Mr. Blake Jensen M.B.A. | Head of Quality |
| Ms. Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Ms. Hilda Maibach | Senior Vice President of Statistics |
| Date | Type | Document |
|---|---|---|
| 2026-06-17 | 8-K | tm2617993d2_8k.htm |
| 2026-05-20 | 8-K | tm2615162d1_8k.htm |
| 2026-05-15 | 10-Q | anvs-20260331x10q.htm |
| 2026-04-30 | DEF 14A | tm261540-3_def14a.htm |
| 2026-04-10 | 8-K | tm2611267d2_8k.htm |
| 2026-03-25 | 8-K | tm269828d1_8k.htm |
| 2026-03-16 | 8-K | tm268976d1_8k.htm |
| 2026-03-13 | 10-K | anvs-20251231x10k.htm |
| 2026-02-12 | 8-K | tm266101d1_8k.htm |
| 2026-01-28 | 8-K | tm264292d1_8k.htm |